-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Text|Pharmaceutical Mission Hills
On September 6, Eli Lilly and Company China announced that the preventive treatment of migraine drug Emgality (galcanezumab) has achieved positive main results in a global multi-center phase 3 clinical study.
CGRP is called calcitonin gene-related peptide
Galcanezumab is a humanized CGRP monoclonal antibody.
The positive result of the CGAX study is a prospective, global multi-center, randomized, double-blind, placebo-controlled Phase 3 study.
The results of the CGAX study showed that the galcanezumab treatment group was significantly better than the placebo group in terms of the number of headache days per month for the primary endpoint; the treatment group was also better than the placebo group in terms of four key secondary endpoints that assess the impact of migraine on function.
It is worth mentioning that in March 2021, Eli Lilly China announced that its other drug, asmiditan, for the acute treatment of adult migraine, has also achieved positive results in the expansion of the global phase 3 clinical study in China.
Migraine is a disabling neurological disease.
Reference materials:
[1] Phase 3 clinical study of the preventive treatment of migraine drug Emgality® (Galcanezumab) achieved positive main research results.
